Cannabidiol (CBD) products, including CBD isolate, are on their way to becoming a multi-billion dollar mainstream industry, due in large part to the cannabinoid’s health and wellness benefits.
CBD products represent one of the fastest-growing segments in the cannabis market as well as the US$4 trillion health and wellness industry. One of the many cannabinoids in the cannabis plant, CBD delivers therapeutic benefits without the high caused by the psychoactive cannabinoid tetrahydrocannabinol (THC).
The Brightfield Group forecasts CBD product sales to reach US$5 billion in 2019 and US$23.7 billion by 2023. Chain stores are expected to generate the majority of those sales. In the US, major retailers such as CVS Pharmacy (NYSE:CVS), Walgreens (NASDAQ:WBA) and Kroger (NYSE:KR) are now stocking their shelves with a wide range of CBD topicals including creams, sprays, roll-ons, oils, lotions and salves.
Presenting The Easiest Way Ever To Know About Teslaâ€™s Battery Day!
Unlocking Key Trends For A Better Way To Invest In Battery Metals.
CBD isolate is one of the more popular forms of cannabidiol used by consumers who are looking for more natural ways to relieve ailments such as pain, inflammation, anxiety and sleep problems.
CBD isolate is cannabidiol in its purest form. As the name implies, the chemical compound is produced by “isolating” or extracting it from the plant material. Although it can be extracted from the marijuana plant, CBD in isolate form is best derived from hemp, a member of the cannabis sativa family that contains high concentrations of CBD and little THC. Hemp growers for the CBD market focus on breeding and cultivating plants with a high CBD ratio and less than 0.3 percent THC.
Hemp’s low THC level is a part of the reason why US legislators removed restrictions on the hemp industry under the December 2018 US Farm Bill. The passage of the bill was a pivotal turning point for the CBD product industry. While cannabis remains federally illegal in the US, hemp is now considered an agricultural product and can be transported and sold throughout the country.
Using dried hemp, CO2 extraction is the preferred process of most CBD isolate manufacturers and considered to be the most effective method for creating high-quality CBD isolate free from residual solvents. The plant material is combined with extremely cool liquid CO2, which creates a solvent that can be heated away to isolate the pure CBD oil. The next step involves purifying the extracted oil through filtration and a final process called winterization, which uses chilly temperatures to remove any remaining plant compounds to produce a 99 percent pure CBD crystalline that can then be ground into a fine powder.
CBD isolate products manufactured by licensed companies and tested by third-party labs must not contain additives or contaminants. According to the World Health Organization, CBD has yet to show any potential for physical dependency, and there is no evidence of any public health issues associated with its use. CBD isolate allows consumers to easily calculate their dosage in order to consume the exact amount of CBD needed. The weight of the isolate is equal to the CBD content in milligrams. When comparing price per milligram of CBD, isolate is also less expensive than other commercial forms of CBD, including full-spectrum CBD, which contains trace amounts of THC.
CBD value-added products
Odorless and tasteless, CBD isolate can be consumed sublingually in its pure powder form or mixed with liquids such as coffee or tea. The powder also blends easily into carrier oils, creams and food products to create a wide variety of health and wellness products. Today, CBD isolate powder is used in the commercial manufacturing of CBD-infused edibles, beverages, capsules and topicals, or it can be mixed with carrier oils to create sublingual CBD products.
One of the most attractive attributes of CBD isolate for consumers is the absence of THC, meaning consumers can reap the health benefits of cannabis without experiencing the high.
CBD’s unique properties have opened up the market to a number of different consumer demographic groups, including those new to cannabis like athletes, mothers with young kids at home, the elderly and even pets. “As we continue to educate the consumer about the fact that there are different cannabinoids that have different impacts, I think a claim of no THC is definitely something that could entice a consumer,” said Rebecca Brown, founder of and cannabis marketer at Crowns Agency. “As with THC, you’ll see CBD consumers across every demographic.”
Global market potential
The massive potential for tax revenue is one of the major incentives for governments to legalize and regulate CBD product sales. “Countries around the world are now looking at cannabis and CBD derived from CBD-rich hemp very differently than they would have in the past. In many ways, it’s a race to modernize the rules and regulations to embrace the trend that’s going on worldwide,” Howard Steinberg, CEO of MYM Nutraceuticals (CSE:MYM,OTCQB:MYMMF), told the Investing News Network. Steinberg said his company believes “that the CBD market will ultimately be far larger than the cannabis market,” primarily because of the seemingly endless possibilities for CBD value-added products.
In July 2019, Market Watch reported that the US Food and Drug Administration (FDA) announced it will “expedit(e) its effort to create a regulatory framework for CBD with plans to publish a report on its progress by early fall.” While the FDA is “tolerating” the sale of CBD-infused topicals and oils in the country, the agency has yet to sanction the addition of CBD to food and beverages. Because CBD is the main ingredient in an FDA-approved drug, GW Pharmaceuticals’ (NASDAQ:GWPH) childhood epilepsy treatment Epidiolex, the agency says it cannot approve further CBD products without research and trials. However, former FDA Commissioner Scott Gottlieb has “proposed congressional action to speed things up, based on using very low doses of the substance.”
To the north, Health Canada is planning to introduce new regulations in October 2019 that will legalize the sale of cannabis-based edibles, beverages, topicals and extracts. The CBC reported that Canadians could begin legally purchasing these products in major retail chains by the end of 2019.
Additional markets for CBD products are emerging in Europe and Asia. The Brightfield Group estimates that the European CBD sales totaled US$318 million in 2018. “In Europe, you can walk by many stores in downtown regions and see numerous CBD products for sale. Europe is one of the fastest-growing markets for CBD products with a projected market approaching US$2 billion by 2023,” said Steinberg, whose company recently expanded into the region with the opening of a CBD distribution office. “We believe the global CBD isolate market will continue to boom for years to come. There is currently a shortage of products in the market and as more global brands create products that include CBD, the demand will only continue to increase.”
MYM Nutraceuticals is building a global footprint and mitigating geographical risk by establishing cultivation operations in Canada, Nevada and Colombia. MYM is also in the process of establishing its own processing facility to turn the CBD-rich biomass produced at its farms into CBD isolate for sale in legal markets.
Cannabis companies like Orion Nutraceuticals (CSE:ORI) and Pure Global Cannabis (TSXV:PURE,OTC Pink:PRCNF,FRA:1QS) are beginning to make progress in the CBD isolate industry. Orion Nutraceuticals owns facilities in Colombia and Canada that are focused on developing CBD products that meet the needs of the sports medicine market, which has recently seen the decriminalization of CBD from regulatory bodies like the World Anti Doping Agency. Pure Global has agreed to a letter of intent with Isodiol International (CSE:ISOL) for the ongoing supply of pharmaceutical and nutraceutical grade CBD isolates and other potential products.
CBD isolate is cannabidiol in its purest form. Once extracted and refined into a powder, isolate can be used to make a wide range of CBD-infused products that provide consumers with the health benefits of cannabis without the high. Regulators around the world are more comfortable approving the use of CBD-only products than recreational cannabis. Without the regulatory concerns that restrict products containing THC, CBD has the potential to expand consumer demographics for cannabis-based products, introducing new consumers to the cannabis industry altogether.
This INNSpired article was written according to INN editorial standards to educate investors.
Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”) an integrated Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, announces the granting of stock options and restricted share units.
The Company has announced that it has granted incentive stock options to directors, officers, employees and consultants of the Company to purchase an aggregate of 1,000,100 common shares under the Company’s Stock Option Plan. Each option is exercisable at a price of $0.16 per common share, expires three years from the date of grant and vest six months from the date of the grant.
The Company has also granted restricted share unit grants, pursuant to the Company’s Restricted Share Unit plan, dated April 1, 2021, totaling 1,548,875 to certain eligible participants.
For further information, please contact:
Igal Sudman, Chairman, Chief Executive Officer and Corporate Secretary
Ayurcann Holdings Corp.
About Ayurcann Holdings Corp.:
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
News Provided by GlobeNewswire via QuoteMedia
A planned business merger between two leading cannabis producers hit a small delay this week as a critical vote got moved.
Keep reading to find out more cannabis highlights from the past five days.
Tilray delays critical shareholder meeting
On Thursday (April 15), Tilray (NASDAQ:TLRY) announced it will be postponing its shareholder vote on the fate of its merger with Aphria (NASDAQ:APHA,TSX:APHA). It will take place on April 30 instead of April 16.
Neither cannabis company offered an explanation for the change. Tilray has asked shareholders to participate in this vote regardless of how many shares they may hold. “Tilray stockholders who have not already voted, or wish to change their vote, are strongly encouraged to do so,” the company said.
This news came days after Aphria shareholders overwhelmingly voted in favor of the business transaction, with a total of 99.38 percent of shareholders voting for the deal to continue. Confirmation from Aphria Chairman and CEO Irwin Simon indicated the partnership was en route to being complete.
This past week Aphria also released financial results for the third quarter of its 2021 fiscal year, in which the firm highlights the overall direction of the company with the Tilray deal.
“We expect to have a tremendous runway for long-term sustainable growth as we build upon our existing foundation in Canada and internationally by increasing the scale of our global operations,” Simon said in a statement.
Cannabis retailer celebrates digital trend
Bidding for the piece, named “Non-Fungible Toke“ started at a price of C$4.20. The retailer plans to donate the proceeds to two charities, Second Harvest and Less.
The latter is designed to counter the carbon footprint of blockchain technology, a common criticism drawn against the rise of NFTs and other novel technologies.
As of 11:00 a.m. EST on Friday (April 16), the NFT bid was up to C$169.11.
Cannabis company news
- The Valens Company (TSX:VLNS,OTCQX:VLNCF) issued its financial report for the first quarter of its 2021 fiscal year. In its results, the company highlights a net revenue uptick of 24.7 percent from the previous quarter, resulting in C$20 million for the period.
- Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) closed a public offering of 5 million subordinate voting shares at a price of C$50 each for total gross proceeds of C$287.5 million. The company celebrated its financial position after an offering in January, which will lead to the pursuit of merger and acquisition targets.
- Australis Capital (CSE:AUSA,OTCQB:AUSAF) appointed Jason Dyck as its new chief science officer and chairman of the firm’s scientific advisory board. Dyck previously served as an executive at Aurora Cannabis (NASDAQ:ACB,TSX:ACB), leading the scientific efforts for the cannabis producer. “I look forward to providing AUSA with advice and direction in its scientific efforts towards bringing innovations to market with immediate and significant commercial appeal,” Dyck said.
- Truss Beverage, a cannabis drinks venture co-owned by Molson Coors Beverage Company (NYSE:TAP,TSX:TPX) and HEXO (NYSE:HEXO,TSX:HEXO), released the details of its new lineup of infused beverages. Six new drinks will become available around the summer and are intended to pair with the season.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Partnerships with Minardi Law , Minorities for Medical Marijuana, CultivatED, and the Georgia Justice Project will include clinics and virtual events across Florida , Georgia , and Massachusetts
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today a series of expungment clinics located throughout south and central Florida as well as virtual events in Georgia and Massachusetts . The clinics are part of the Company’s celebration of the 50 th anniversary of 420.
During the month of April, Minardi Law has hosted expungment clinics and will be hosting two more as follows:
- Releaf Patient Appreciation Day, April 17 th ( Valrico )
- First Annual 4/20 Event ( St. Petersburg Beach )
At these clinics, an attorney will be present to review records and see if someone is eligible for a sealing or expungment of their records. As part of the events, Trulieve will be helping cover the costs for finger prints, legal fees, and court costs.
Trulieve is working with Minorities for Medical Marijuana (“M4MM”) to host a 4/20 Expungement Clinic, part of M4MM’s Project Clean Slate. This event will take place on Saturday, April 24, 2021 , from 9:30am – 4:30pm at Riviera Beach City Hall. Anyone seeking to take place in this event is required to register in advance at http://trulieve.cc/expungementpreregistration .
In addition, Trulieve is sponsoring the First Friday Series , a weekly virtual event from the Georgia Justice Project to help Georgia citizens with record restrictions, and is also sponsoring the Fellowship Presentation and Expungement Clinic being offered through CultivateEd and GBLS on Friday, April 23 from 3:00pm – 4:00pm . You can register for the Massachusetts expungement clinic in advance here: HTTPS://BIT.LY/2Q655KK
“Our mission as a company has always been to improve people’s lives,” said Trulieve CEO Kim Rivers . “We’ve always been dedicated to improving the communities we call home. Partnering with Minardi Law , Minorities for Medical Marijuana, Georgia Justice Project and CultivatED on these clinics was a simple decision for us; we encourage anyone seeking help with the expungement process to attend one of these clinics in your own state to start the process.”
For more information about Trulieve and the April expungment clinics, please visit www.Trulieve.com .
Trulieve is primarily a vertically integrated “seed-to-sale” company in the U.S. and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also has operations in California , Massachusetts , Connecticut and Pennsylvania. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.
To learn more about Trulieve, visit www.Trulieve.com .
SOURCE Trulieve Cannabis Corp.
News Provided by PR Newswire via QuoteMedia
Seth Rogen’s New Cannabis Brand are Now Available at Apothecarium Dispensaries in San Francisco , Berkeley and Capitola
The Apothecarium is offering cannabis from Houseplant, the cannabis lifestyle brand founded by Seth Rogen and Evan Goldberg at its five California dispensaries. The Apothecarium has three San Francisco locations (Castro, SOMA and Marina ) and one each in Berkeley and Capitola (outside of Santa Cruz ).
“With the vast number of dispensaries in California , we put a lot of effort into identifying the right ones that align with Houseplant’s values,” said Seth Rogen , Co-Founder of Houseplant. “The Apothecarium shares the same commitment to creating a strong consumer experience that we pride ourselves on and we are thrilled to bring our three initial strains to their stores in the Bay Area.”
Houseplant is launching with three flower strains, all of which will be available at The Apothecarium, including: Diablo Wind (sativa), Pancake Ice (sativa) and Pink Moon (indica). Like their founder’s groundbreaking film “Pineapple Express”, Houseplant strains are named after weather phenomena. Each strain will be sold in a custom tin.
“We are so proud to be one of the very first dispensaries in California to offer Houseplant to our customers,” said Ryan Hudson , CEO and co-founder of The Apothecarium. “Seth, Evan and everyone at Houseplant love and respect cannabis as much as we do. We simply cannot wait to share their beautiful and delicious flowers with our guests.”
“We’ve been working with the Houseplant team for more than a year and are grateful to have a partner that shares so many of our values, including an emphasis on cannabis education, quality, reform of cannabis laws and beautifully designed, recyclable packaging.”
“Seth has been hands-on during the process, spending time with our store managers to make sure they know the products and how much care has gone into vetting and selecting the best strains. We think our guests are going to love Houseplant.”
About The Apothecarium
The Apothecarium is recognized as one of the nation’s premier cannabis dispensaries, with an emphasis on education via in-depth one-on-one consultations from highly trained cannabis consultants. The company was founded by three first cousins and two family friends in 2011. Our dispensaries are known for providing educational events that are open to the public at no cost — and for welcoming seniors, first-time dispensary visitors, and people with serious medical conditions. The Apothecarium’s flagship San Francisco dispensary was named the best-designed dispensary in the country by Architectural Digest . Patients and customers may order at our dispensaries or online for pickup or delivery at apothecarium.com [apothecarium.com] .
The Apothecarium is committed to giving back to the communities we serve. We have donated more than $400,000 in cash to community groups and nonprofits — plus more than $300,000 worth of in-kind donations.
All Apothecarium dispensaries continue to implement safety measures to protect guests and team members. Protocols include strict social distancing inside and outside the dispensaries, a mask requirement for everyone inside the dispensaries, no contact check-in procedures and ongoing sanitizing throughout the day.
CA Licenses: C10-0000523-LIC; C10-0000522-LIC; C10-0000515-LIC, C10-0000738-LIC, C10-0000706-LIC
News Provided by Canada Newswire via QuoteMedia
MISSISSAUGA, Ontario TheNewswire – April 16, 2021 Sire Bioscience Inc. (CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (CNSX:SIRE.CN) (“SIRE” or the “Company”) announces that Brian Nugent has resigned as a member of the Company’s board of directors (the “ Board ”). It has been a pleasure and a blessing to have worked with Brian Nugent over the past few years, his business acumen and tremendous experience will certainly be missed, SIRE wishes him nothing but the best in all his future endeavors.
About Sire Bioscience
SIRE is headquartered in Mississauga, Ontario with its wholly owned subsidiary PLANTFUEL® based in Denver, Colorado. SIRE is managed by a group of successful entrepreneurs who have extensive experience in the areas of consumer-packaged goods, manufacturing, logistics, and distribution. SIRE is a CPG life science company focused on the plant-based foods and supplements industry.
For additional information contact:
Sire Bioscience Inc.
Copyright (c) 2021 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia